CHAPEL HILL, N.C., May 12, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2015, May 15-20, and the Community Acquired Pneumonia Organization (CAPO) Symposium on May 20-21. Both meetings are being held in Denver.
Presentation at ATS 2015:
- Oral Solithromycin Versus Oral Moxifloxacin for Treatment of Adult Community-Acquired Bacterial Pneumonia (CABP): Results of the Global Phase-3 Trial SOLITAIRE-ORAL – Poster, Poster Board #920, Mile High Ballroom 1 E-F (Lower Level), Colorado Convention Center, May 19, 9:30 a.m. MDT. An abstract is available using the link Solithromycin ATS.
CAPO Pneumonia Symposium:
- The goal of CAPO is to foster global clinical and translational research in pneumonia and influenza. Cempra will present data related to the Solitaire clinical trials database and biorepository, May 21, 3:00 p.m. MDT, at the Embassy Suites, Downtown Convention Center Hotel.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin has also entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACT: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 email@example.com Media Contacts: Russo Partners, LLC Robert E. Flamm, Ph.D. (212) 845-4226 firstname.lastname@example.org Lena Evans (212) 845-4262 email@example.com